Keywords: EMEA< GlaxoSmithKline, Avandia
European Medicines Agency holds back on GlaxoSmithKline Avandia decision
Article | 23 July 2010
The European Medicines Agency (EMEA) announced yesterday that it is still reviewing GlaxoSmithKline's controversial diabetes drug Avandia (rosiglitazone), which has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
